UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021

August 9, 2021 Auto Bot bimekizumab, Clinical Trials, Plaque Psoriasis, UCB 0

Shots:

  • The ongoing BE BRIGHT, OLE trial evaluates the safety, tolerability, and efficacy of bimekizumab (q4w/q8w) in 989 patients with the mod. to sev. PsO
  • The interim data showed that @16wks., 9/10 patients achieved clear or almost clear skin (IGA 0/1), 8/10 patients achieved complete skin clearance (PASI 100) and maintained responses through 2yrs. with continuous maintenance dosing
  • Bimekizumab is an investigational humanized IgG1 mAb that selectively inhibits both IL-17A & IL-17F. The therapy is currently under the FDA’s review for the mod. to sev. PsO in adults while EC’s decision on MAA is expected within ~ 2mos of CHMP’s opinion

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Contract Pharma

The post UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021 first appeared on PharmaShots.